



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/756,761	01/14/2004	Laurence S. Harbige	604-706	1504
23117	7590	10/02/2007		
NIXON & VANDERHYE, PC 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203			EXAMINER KANTAMNENI, SHOBHA	
			ART UNIT 1617	PAPER NUMBER
			MAIL DATE 10/02/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/756,761

Applicant(s)

HARBIGE ET AL.

Examiner

Shobha Kantamneni

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 July 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-15 is/are pending in the application.
- 4a) Of the above claim(s) 4 and 5 is/are withdrawn from consideration.
- 5) ☒ Claim(s) NONE is/are allowed.
- 6) ☒ Claim(s) 1-3 and 6-15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 04/28/05, 04/19/05.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-15 are pending.

Election/Restrictions

Claims 4-5 are withdrawn from consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions.

Applicant's election of invention Group II, Claim 1-2 (in part), 3, 6-15 (in part), drawn to a method of treating a patient for multiple sclerosis comprising administering a therapeutically effective dose of a compound of formula I, wherein X¹, X², and X³ being nitrogen, in the reply filed on 07/13/2007 is acknowledged herein. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The requirement is made FINAL.

Claims 1-3, and 6-15 are examined herein, insofar as they read on the elected invention.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-3, 8-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The recitation wherein Y1 and Y2 are selected from "secondary and tertiary amino groups" in claim 1 is vague and indefinite, as it is not clear what compounds this term encompasses, and since one of ordinary skill in the art could not ascertain the metes and bounds as to "secondary and tertiary amino groups". The specification merely recites that preferably Y1 is selected from - 1-piperazinyl and 4-alkyl- 1-piperazinyl ". See page 4, line 15-16. However, it is not clear what other compounds are encompassed by these terms because secondary amines have two organic substituents attached to N together with one hydrogen, and tertiary amino groups have three organic substituents attached to the N, and thus it is not clear what kind of substituents are attached to the N in case of secondary and tertiary amino groups.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 6-9, 11-12, and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Lunardi et al. (Neurology, volume 48(6), 1997, pages 1714-1717, PTO-892).

Lunardi et al. discloses administration of lamotrigine to patients suffering from multiple sclerosis in which trigeminal neuralgia was also present. See abstract; page 1715. Lamotrigine was administered at an initial dosage of 25 mg/day, increasing in

Art Unit: 1617

increments of 25 mg every third day up to a maximum absolute dosage of 400 mg/day. See page 1716, left hand column. Administration of lamotrigine to patients suffering from multiple sclerosis concomitant with trigeminal neuralgia resulted in complete pain relief.

It is pointed out that Lunardi et al. method inherently treats multiple sclerosis, since the method steps are same as the instant method steps, administering the same compound in the same effective amount to the same or overlapping patient population will cause the same effect, whether or not that effect is specifically disclosed by the prior art.

Further, regarding the recitations, "wherein the therapy results in reduction of one or more of incidence of relapse, spasticity and fatigue", "wherein the therapy stabilizes the patients Expanded Disability Status Score, thus halting progress of the disease", in claims 8-9, Lunardi et al. method inherently results in reduction of one or more of incidence of relapse, spasticity and fatigue", inherently halts progress of the disease, as claimed herein since Lunardi's method steps are same as the instant method steps, administering the same compound in the same amount to a patient suffering from multiple sclerosis. See *Ex parte Novitski*, 26 USPQ 2d 1389, 1391 (Bd. Pat. App. & Int. 1993). See also *Eli Lilly and Co. v. Barr Laboratories Inc.* 251 F3d. 955; 58 USPQ2d 1869-1881 (Fed. Cir. 2001) with regard to inherency as it related to the claimed invention herein.

Thus, Lunardi et al. anticipates instant Claims 1-3, 6-9, 11-12, and 15.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3, 6-9, 11-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Bountra et al. (WO 00/61231, PTO-1449).

Bountra et al. discloses a method of treating multiple sclerosis comprising administering sodium channel antagonists such as 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine called lamotrigine, 5-amino-6-[2,3,5-trichlorophenyl]-1,2,4-triazine. See page 7, lines 20-24; page 8, lines 5-10. A dose range of 200 mg/day to 900 mg/day for an adult human is disclosed. See page 10, lines 1-8.

Regarding the recitations, "wherein the therapy results in reduction of one or more of incidence of relapse, spasticity and fatigue", "wherein the therapy stabilizes the patients Expanded Disability Status Score, thus halting progress of the disease", in claims 8-9, Bountra et al. method inherently results in reduction of one or more of incidence of relapse, spasticity and fatigue", inherently halts progress of the disease, as claimed herein since Bountra's method steps are same as the instant method steps, administering the same compound in the same amount to a patient for treating multiple sclerosis. See *Ex parte Novitski*, 26 USPQ 2d 1389, 1391 (Bd. Pat. App. & Int. 1993). See also *Eli Lilly and Co. v. Barr Laboratories Inc.* 251 F3d. 955; 58 USPQ2d 1869-

Art Unit: 1617

1881 (Fed. Cir. 2001) with regard to inherency as it related to the claimed invention herein.

Thus, Bountra et al. anticipates instant Claims 1-3, 6-9, 11-13.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 10, 14-15 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Bountra et al. (WO 00/61231, PTO-1449) as applied to claims 1-3, 6-9, 11-13.

Bountra et al. discloses a method of treating multiple sclerosis comprising administering sodium channel antagonists such as 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine called lamotrigine, 5-amino-6-[2,3,5-trichlorophenyl]-1,2,4-triazine. See page 7, lines 20-24; page 8, lines 5-10. A dose range of 200 mg/day to 900 mg/day for an adult human is disclosed. Bountra et al. also teaches that it may be necessary to make routine variation to the dosage, depending on the age and condition of the patient. See page 10, lines 1-8.

Bountra et al. does not specifically teach the amount of lamotrigine as 600 mg/day as in claim 14, and the dosing regimen as in claim 15.

Art Unit: 1617

It would have been obvious to a person of ordinary skill in the art at the time of invention to determine or optimize parameters such as effective amounts of lamotrigine to be administered in the method of treating multiple sclerosis.

One having ordinary skill in the art at the time the invention was made would have been motivated to determine the effective amounts of lamotrigine employed in the method of treating multiple sclerosis, since the optimization of effective amounts of known agents to be administered, is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art.

It has been held that it is within the skill in the art to select optimal parameters, such as amounts of known ingredients in order to achieve a beneficial effect. See *In re Boesch*, 205 USPQ 215 (CCPA 1980).

One of ordinary skill in the art at the time of invention would have been motivated to the particular treatment regimen because the optimization of result effect parameters e.g., dosage range, dosing regimens, dosing duration is obvious as being within the skill of the artisan, involving merely routine skill in the art.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shobha Kantamneni whose telephone number is 571-272-2930. The examiner can normally be reached on Tuesday-Thursday, 8am-4pm.

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, Ph.D can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-272-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Shobha Kantamneni, Ph.D
Patent Examiner
Art Unit : 1617

A handwritten signature in black ink, appearing to read 'Sreeni Padmanabhan', written in a cursive style.

SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER